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Tweet:
 
@MelindaCoughlan @sihmin_tan @CCSMonash @MonashDiabetes 
A new immunometabolic pathway uncovered in diabetes! Innate immune Complement C5a 
induces kidney injury in diabetes by disrupted mitochondrial agility.
#diabetes #kidney #mitochondria #complement #immunometabolism
Figure 6 best summarizes the article
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4Abstract
The sequelae of diabetes mellitus include microvascular complications such as diabetic kidney 
disease (DKD), which involves glucose-mediated renal injury that is associated with a disruption 
in mitochondrial metabolic agility, inflammation and fibrosis. We explored the role of the innate 
immune complement component C5a, a potent mediator of inflammation, in the pathogenesis of 
DKD in clinical and experimental diabetes. Marked systemic elevation in C5a activity was 
demonstrated in patients with diabetes which was not therapeutically targeted by conventional 
renoprotective agents. C5a and its receptor (C5aR1) were upregulated early in the disease process 
and prior to manifest kidney injury in several diverse rodent models of diabetes. Genetic deletion 
of C5aR1 in mice conferred protection against diabetes-induced renal injury. Transcriptomic 
profiling of kidney revealed diabetes-induced downregulation of pathways involved in 
mitochondrial fatty acid metabolism. Interrogation of the lipidomics signature revealed abnormal 
cardiolipin remodelling in the diabetic kidney, a cardinal sign of disrupted mitochondrial 
architecture and bioenergetics. In vivo delivery of an orally active inhibitor of C5aR1 (PMX53) 
reversed the phenotypic changes and normalized the renal mitochondrial fatty acid profile, 
cardiolipin remodelling and citric acid cycle intermediates. In vitro exposure of human renal 
proximal tubular epithelial cells to C5a led to altered mitochondrial respiratory function and 
reactive oxygen species generation. These studies provide evidence for a pivotal role of the 
C5a/C5aR1 axis in propagating renal injury in the development of DKD via disruption of 
mitochondrial agility, establishing a new immunometabolic signalling pathway in DKD. 
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5Diabetic kidney disease (DKD), affecting up to 30% of patients with both type 1 (T1D) and type 
2 diabetes (T2D), is the leading cause of end stage renal disease in Western societies (1; 2). Despite 
optimal conventional management with pharmacological inhibition of the renin angiotensin 
system (RAS), glycemic and blood pressure control, a significant proportion of patients with DKD 
still progress over time to end stage renal failure. Thus, the identification of new molecular 
pathways with opportunity for therapeutic targeting to slow, halt and/or potentially reverse DKD 
progression would address a major area of unmet need.
The diabetic kidney is exposed to persistent metabolic and haemodynamic stressors resulting in 
cellular injury and activation of the innate immune response, including the complement system 
(3). The complement system is a highly sophisticated network of proteins that are activated in 
response to invading pathogens or tissue injury. Complement homeostasis is finely balanced and 
when subject to states of dysregulation or hyperactivation can propagate a severe inflammatory 
response (4). Complement comprises three mechanistic pathways; classical, lectin and alternative, 
with activation of any one of these commonly converging to the production of the complement C3 
and C5 convertases. These enzymes cleave complement subtrates C3 and C5 respectively, 
resulting in the generation of the opsonic C3b, anaphylatoxins C3a and C5a and subsequently the 
formation of membrane attack complex (MAC; comprising C5b-9). As the terminal effector 
component of complement cascade, the MAC lyses, damages, or activates target cells to drive 
inflammation (5). All complement activation pathways result in the formation of C5a, a potent and 
a major effector molecule of complement, which, via ligation with the receptor C5aR1, initiates 
and propagates pathology in inflammatory disease states (6). The role of the C5a-C5aR1 signalling 
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6cascade has been implicated in a number of kidney diseases in both animal models (7-10) and 
humans (11), however its role in DKD-associated renal injury is poorly defined. 
Here, we reported that in patients with diabetes, complement is hyperactivated in both type 1 and 
type 2 diabetes, and not targeted by conventional DKD trajectory modifying therapies such as RAS 
inhibitors. C5a was generated and C5aR1 upregulated in the kidney of several models of 
experimental diabetes and prior to the onset of albuminuria. Inhibition of C5aR1 via genetic 
deletion or pharmacological targeting with PMX53 in streptozotocin-induced diabetic mice 
improved albuminuria and renal injury. Interrogation of the lipidomics signature revealed 
abnormal cardiolipin remodelling in the diabetic kidney, a cardinal sign of disrupted mitochondrial 
architecture and bioenergetics. Inhibition of the C5a/C5aR axis restored the renal mitochondrial 
fatty acid profile, most notably cardiolipin, and targeted metabolomics showed normalization of 
citric acid cycle intermediates. Proof of concept studies in human primary proximal tubule cells 
showed that C5aR1 signalling disrupts mitochondrial respiratory function and induces reactive 
oxygen species generation. Taken together, our results show that the C5a/C5aR1 axis propagates 
renal injury in DKD via mitochondrial reprogramming and establishes complement C5a as a new 
immunometabolic signalling pathway in DKD.
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7Methods
Patient recruitment and blood sample collection
The study was approved by the Human Research Ethics Committee at Austin Health and Alfred 
Health and was conducted in accordance with the principles of the Declaration of Helsinki. 
Participating in this study were individuals with type 1 diabetes (T1D) or type 2 diabetes (T2D) 
drawn from a population of patients attending the diabetes clinic at the Austin and Repatriation 
Medical Centre, Melbourne, Australia. As the primary referral base (80%) is from general 
practitioners, with only 20% referred from within the hospitals, the cohort is representative of 
patients with diabetes seen in the wider community. Patient recruitment methods have been 
described previously (12). A non-diabetic control group was also recruited from Austin Health and 
the Baker Heart and Diabetes Institute (Alfred Health). Written informed consent was obtained 
from all participants who donated blood. EDTA plasma was collected by centrifuging blood at 
3500 rpm at 4C for 15 min and storing at -80C.
Assessment of complement components in human plasma
Commercially available ELISA kits were used to determine plasma C5a (BD OptEIA), C3a (BD 
OptEIA) and C5b-9 (MicroVue Quidel) according to the manufacturer’s instructions. 
Animal experiments
All animal experiments were performed in accordance with guidelines from the Alfred Medical 
Research and Education Precinct (AMREP) Animal Ethics Committee and the National Health 
and Medical Research Council of Australia. All rodents were housed in a temperature-controlled 
environment, with a 12-h light/dark cycle and access to chow (Specialty Feeds, Perth, WA, 
Australia) and water ad libitum. C57BL/6J and C5aR1-/- mice backcrossed onto a C57BL/6 
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8background (gift of Prof Rick Wetsel, University of Texas (13)) were bred at AMREP Animal 
Services. Ins2-Akita mice (C57BL/6-Ins2Akita/J) were purchased from the Jackson Laboratory (Bar 
Harbor, ME).  Six week old heterozygous Ins2-Akita mice and their wildtype littermates were 
followed for 20 weeks. Db/db mice (lepr(+/+)C57 BL/KsJ) and db/h controls were purchased from 
the Jackson Laboratory and a colony maintained at AMREP Animal Services. Six week old db/db 
and db/h mice were followed for 14 weeks. Sprague-Dawley rats were sourced from AMREP 
Animal Services. Experimental diabetes was induced in six week old male Sprague Dawley rats 
(200-250g) by i.v. injection of streptozotocin (50mg/kg, sodium citrate buffer pH 4.5) following 
an overnight fast. The rat timecourse model has been previously described (14).
Diabetes was induced in 6-week-old mice by five daily intraperitoneal injections of low-dose 
streptozotocin (55 mg/kg; Sigma-Aldrich, St. Louis, MO). Non-diabetic group was given 0.5M 
sodium citrate. For the knockout study, diabetic and non-diabetic wildtype (n=7-10) and C5aR1-/- 
(n=4-12) mice were followed for 24 weeks after onset of diabetes. For the PMX53 study, diabetic 
and nondiabetic mice were randomized to receive either (a) the C5aR1 peptide inhibitor PMX53 
(Ac-Phe-[Orn-Pro-dCha-Trp-Arg]) (synthesized as previously described (15)) at 2mg/kg body 
weight provided in the drinking water, or (b) drinking water alone (n=6-12), and followed for 24 
weeks. At the end of the study, plasma and kidneys were collected for analysis.
Assessment of renal function and metabolic parameters
Plasma glucose was measured using a glucose colorimetric assay kit (Cayman Chemical). 
Glycated hemoglobin (GHb) was determined using a Cobas Integra 400 Autoanalyzer (Roche 
Diagnostics Corporation, USA). Urinary albumin was measured using a mouse albumin ELISA 
kit (Bethyl Laboratories, Montgomery, TX). Plasma cystatin C was determined using a 
commercially available ELISA kit from R&D Systems (MN, USA). Urinary C5a was measured 
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9using a mouse Complement Component C5a DuoSet ELISA kit (R&D Systems). Urinary 8-
isoprostane was measured using an 8-isoprostane ELISA kit (Cayman Chemical). Urine and 
plasma creatinine were measured using the Creatinine plus ver.2 (CREP2) on a Cobas Integra 400 
plus (Roche Diagnostics). Plasma IL-18 was measure using a mouse IL-18 ELISA kit (Invitrogen, 
Carlsbad, Ca).
Renal histology
Kidney sections (3µm) were stained with periodic-acid Schiff (PAS) and picrosirius red. For PAS-
stained sections, the degree of sclerosis in each glomerulus was subjectively graded on a scale of 
0-4 with grade 0 = normal; grade 1 = sclerotic area up to 25% (minimal); grade 2 = sclerotic area 
25-50% (moderate); grade 3 = sclerotic area 50-70% (moderate to severe), and grade 4 = sclerotic 
area 75-100% (severe). The GSI was then calculated using the following formula: GSI = (1 × n1) 
+ (2 × n2) + (3 × n3) + (4 × n4)/n0 + n1 + n2 + n3 + n4, where nx is the number of glomeruli in 
each grade of glomerulosclerosis. Mesangial index was analysed from digital images of glomeruli 
using Image-Pro Plus v6.0 (Media Cybernetics, Bethesda, MD, USA) and expressed as percentage 
of PAS-stained area per glomerular cross-sectional area. For picrosirius red-stained sections, 
positive collagen staining (red) was examined under light microscopy (Olympus BX-50; Olympus 
Optical) and digitized with a high-resolution camera. All digital quantitation (Image-Pro Plus, 
v6.0) and assessments were performed in a blinded manner.
Immunohistochemistry
Paraffin sections of mouse kidney (4µm) were immunostained for FoxP3 (clone, FJK-16s; 
Affymetrix eBioscience), F4/80 (clone CI:A3-1; Abcam) or collagen IV (Southern Biotech). 
Briefly, endogenous peroxidases were blocked with 3% hydrogen peroxide for 15min and 
incubated in 0.5% skim milk/TBS for 1 hour at room temperature. Primary antibody was left on 
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overnight at 4⁰C. This was followed by incubation with biotinylated secondary antibody for 10min 
at room temperature. Sections were then incubated with Vectastain ABC reagent (Vector 
Laboratories, CA, USA). Peroxidase activity was identified by reaction with 3,3’-
diaminobenzidine tetrahydrochloride (Sigma-Aldrich Pty. Ltd, NSW, Australia). Sections were 
counterstained with haematoxylin. All sections were examined under light microscopy (Olympus 
BX-50; Olympus Optical) and digitized with a high-resolution camera. All digital quantitation 
(Image-Pro Plus, v6.0) and assessments were performed in a blinded manner. 
Quantitative real-time RT-PCR
RNA from kidney cortex and liver was extracted using TRIzol Reagent and cDNA synthesized as 
described previously (16). Gene expression was determined using a 7500 Fast Real-time PCR 
System (Applied Biosystem, VIC, Australia). Gene expression was normalized relative to 18S 
ribosomal RNA, and the relative fold difference in expression was calculated using the 
comparative 2-ΔΔCt method.
RNA sequencing and analysis
Some 200ng of total RNA underwent ribosomal RNA depletion using the NEBNext® rRNA 
Depletion Kit followed by library construction using NEBNext® Ultra II™ Directional RNA 
Library Prep Kit for Illumina® (both from NEB, USA). Barcoded libraries underwent Illumina 
100 cycle single read sequencing at AGRF, Melbourne using HiSeq v4 reagents. Reads underwent 
3’ trimming to remove bases with quality less than Phred 20 using Skewer (17) and were mapped 
with to the Ensembl mouse genome (GRCm38) using STAR (18). The resulting count matrix 
underwent differential analysis with the EdgeR package (19). Genes were ranked from most up-
regulated to most down-regulated by multiplying the sign of the log2 fold change by the inverse 
of the p-value. This preranked list was used for pathway analysis using GSEA (20) with 
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REACTOME gene sets (21). Multi-contrast enrichment was undertaken as described previously 
(22).
Lipidomics
Renal cortical tissues were homogenized and sonicated in phosphate buffered saline (PBS) 
(pH7.4). Protein concentration was determined using the bicinchoninic acid (BCA) assay (Thermo 
Scientific). Lipid extraction was performed as previously described (23). Lipidomic analyses of 
the lipid extract were performed by liquid chromatography electrospray ionization tandem mass 
spectrometry modified from (24), using an AB Sciex Qtrap 4000 coupled to an Agilent 1200 
HPLC. Free fatty acids were measured under the same chromatographic conditions but in negative 
ionization mode. Data were analyzed using Multiquant software 2.1.1 and specific lipid species 
were normalized to total phosphatidylcholine (PC) levels. Some lipid species were also normalized 
to total protein as an alternate normalization strategy. 
Metabolomics
Tissue metabolites from the kidney cortex were extracted using a cryogenically cooled bead mill 
(25). Metabolite extracts were derivatized and analyzed by GC-MS (26). The resultant data matrix 
of integrated metabolite areas was log-transformed and median normalized prior to statistical 
analysis using MetaboAnalyst v4.0 or GraphPad Prism v7.0.
Proximal tubule cell culture and mitochondrial respiratory function
Human primary proximal tubule cells obtained from American Type Culture Collection (ATCC, 
USA) were maintained in Renal Epithelial Cell Basal Medium (ATCC) supplemented with the 
Renal Epithelial Cell Growth Kit (ATCC). PTECs, at 70-90% confluency, were seeded into 96-
well XF96 cell culture microplates (Seahorse Bioscience) at 22,000 cells per well and then left to 
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recover for 24h in Renal Epithelial Cell Basal Medium. Cells were washed and incubated at 37°C 
in DMEM containing either recombinant human C5a (500ng/ml, R&D Systems) or 500ng/ml C5a 
plus 2.5μM PMX53, pH 7.4 for 24 hours. The mitochondrial bioenergetic profile of primary human 
PTECs was assessed using the Seahorse XF96 Flux Analyzer (Seahorse Bioscience, North 
Billerica, MA) applying the mitochondrial stress test. Three basal oxygen consumption rate (OCR) 
measurements were performed and these were then repeated following sequential exposure to the 
ATP synthase inhibitor oligomycin (1μM), the proton ionophore carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone (FCCP, 0.75μM) and the complex III inhibitor Antimycin A 
(2μM) and rotenone (0.5μM). Calculation of mitochondrial respiratory function was then 
completed (27). At the end of the assay, cells were lysed and protein concentration was determined 
in each well using the BCA protein assay kit (Thermo Scientific) according to the manufacturer’s 
instructions.
Reactive oxygen species generation
Human primary PTECs, described above, were cultured in T25 cell culture flasks (1x106 cells) 
and were exposed to 20nM human C5a (Complement Technology, TX, USA) or 20nM C5a plus 
2.5μM PMX53 for 24 hours. After harvesting and resuspending in Hanks balanced salt solution 
(HBSS, with sodium bicarbonate, calcium and magnesium, 10 mM HEPES, without phenol red, 
pH 7.4.), cells were incubated with 10 M 5',6'-chloromethyl-2',7'dichlorodihydro-fluorescein 
diacetate (CM-H2DCFDA, Molecular Probes, Eugene, OR, USA) for 30 min at 37C in the dark. 
The cells were washed twice with HBSS and analyzed on a FACS Calibur (BD, USA) flow 
cytometer. A minimum of 15,000 cells per sample were analyzed. 
Statistical analyses
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The data are expressed either as scatterplots of the data showing the mean, or as mean ± 
standard error of mean (SEM). Statistical analyses were performed using GraphPad Prism version 
7.0 (GraphPad Software, La Jolla, CA, USA). For the clinical studies, One-way ANOVA with 
Tukey’s post-test analysis was used to determine statistical significance. Data not normally 
distributed were analyzed after logarithmic transformation. For the C5aR1 knockout study, all data 
were analyzed by two-way ANOVA with Tukey’s post hoc testing, unless otherwise stated. For 
the PMX53 study, all data were analyzed by one-way ANOVA with Tukey’s post hoc testing, 
unless otherwise stated. Comparison between two groups was performed using two-tailed 
Student’s t-test. If data were non-parametric, a Mann Whitney test was used. A P value <0.05 was 
considered statistically significant. Pearson’s correlation was used to determine relationship 
between variables. Lipidomics data were analyzed using R (3.4.0) and all p-values were corrected 
for multiple comparisons using the method of Benjamini and Hochberg, controlling for the false 
discovery rate (FDR) (28). 
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Results 
Both type 1 and type 2 diabetes are associated with activation of the distal pathway of 
complement, which is not targeted by conventional DKD trajectory modifying therapies 
We explored whether the terminal complement components, including the major effector 
molecules C3a and C5a, and the terminal complement component C5b-9 (MAC) were altered in 
type 1 diabetes (T1D) and in type 2 (T2D) diabetes. Markedly elevated levels of C5a, C3a and 
C5b-9 were found in plasma from normoalbuminuric patients with T1D and T2D compared to 
non-diabetic controls (Fig. 1A-C, Table S1). These data clearly indicate that the C5aR1 axis is 
activated in human diabetes prior to DKD development. Since the first line therapy for patients 
with DKD is RAS inhibition, we determined whether this commonly used therapy could affect 
complement activation. The elevated level of plasma C5a, C3a and C5b-9 in patients with diabetes 
was not normalised in subjects treated with RAS inhibition (Fig. 1 A-C, Table S1). In patients with 
diabetes, there was a correlation between plasma C5a and urine albumin (r=0.25, p=0.09), 
however, this did not reach significance (Fig. S5A). Further, there was a negative correlation 
between plasma C5a and eGFR (=-0.32), however, this did not reach significance (p=0.06, Fig. 
S5B).
C5a/C5aR1 is upregulated in multiple animal models of diabetes
To investigate if complement is also activated in experimental diabetes, we evaluated the status of 
this axis in two disparate models, an insulin deficient model, the Ins2-Akita mouse model (a 
genetic model of T1D, Fig. 2A) and an insulin resistant model, the db/db mouse model (a genetic 
model of T2D and obesity, Fig. 2D). Indeed, C3, C5 and C5aR1 transcripts were upregulated in 
the kidney in both mouse models of diabetes compared to their wildtype littermates (Fig. 2A and 
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D). Since the liver is the major site of complement biosynthesis, hepatic complement levels are 
largely reflective of systemic complement (29). Within the liver, C3 and C5aR1 transcripts were 
upregulated in both the Ins2-Akita and db/db mice (Fig. 2B and E). In addition, urinary excretion 
of C5a was markedly increased (Fig. 2C and 2F), indicating that the C5a/C5aR1 axis is upregulated 
in experimental diabetes and DKD, consistent with the human condition. 
C5a/C5aR1 upregulation in diabetes occurs prior to the development of renal injury
To determine the timecourse of C5a activation in the development of DKD, we mapped urinary 
C5a excretion and renal C5aR1 expression in a rat model of STZ-induced T1D. We have 
previously characterized the onset of glomerular injury in STZ-diabetic rats (14). In diabetic rats, 
preceding the onset of albuminuria (evident at 16 weeks (14)), at four weeks after the establishment 
of diabetes, there was a significant increase in C5aR1 expression in renal cortex (Fig. 2G) and a 
trend toward an increase in urinary excretion of C5a, which reached significance at 16 weeks and 
persisted to 32 weeks (Fig. 2H). Taken together, these results suggest that upregulation of 
C5a/C5aR1 occurs prior to the development of detectable renal injury, consistent with complement 
activation playing an early key injurious role in DKD pathogenesis. 
Genetic deletion of C5aR1 improves diabetes-induced renal injury
To assess the effect of genetic deletion of C5aR1 on the development of DKD, C5aR1-/- mice on 
a C57BL/6 background and their wildtype littermates were treated with STZ to induce diabetes. 
The metabolic characteristics of the mice are shown in Table 1. Plasma cystatin C was lower in 
wildtype diabetic mice and in C5aR1-/- diabetic mice compared to wildtype control mice (Table 
1). Although there was no statistically significant difference between WT control and C5aR1-/- 
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control mice, control C5aR1-/- mice tended to exhibit hyperfiltration. Wildtype diabetic mice had 
a 20-fold increase in urinary excretion of albumin compared to control mice (Fig. 3A), whilst 
deletion of C5aR1 reduced by >75% diabetes-induced albuminuria (Fig. 3A). Deletion of C5aR1 
also inhibited oxidative stress in the setting of diabetes as reflected by a decrease in 8-isoprostanes 
(Fig. 3B). 
Infiltrating macrophages in the tubulointerstitium as assessed by F4/80 immunohistochemistry 
were increased in wildtype diabetic mice (Fig. 3C, E). Deletion of C5aR1 abrogated the increase 
in F4/80 positive cells in the tubulointerstitium in diabetic mice (Fig. 3C, E). Forkhead box P3 
(FoxP3) regulatory T cells (or Treg) are thought to play a role in ameliorating inflammation in the 
diabetic kidney (30). We found a reduced number of FoxP3 positive cells in the tubulointerstitium 
of wildtype diabetic mice (Fig. 3D, E). C5aR1 deletion resulted in protection against FoxP3+ Treg 
depletion in the setting of diabetes (Fig. 3D, E).
Pharmacological inhibition of C5a/C5aR1 with PMX53 is efficacious in DKD
PMX53 is an orally active cyclic peptide antagonist of C5aR1 (6). Prior to administration to a 
mouse model of diabetes, we performed pharmacokinetic experiments with PMX53 in C57BL/6J 
mice (methods in Supplementary material). The plasma concentrations versus time profile of 
PMX53 via i.v. and p.o. routes demonstrated a curvilinear pattern, with a rapid clearance (Fig. S1), 
with the pharmacokinetic parameters reflecting a fast absorption and distribution of the drug (Table 
S2). An oral bioavailability of ~6% was determined as calculated by the ratio of area under the 
curve.
Treatment of STZ-diabetic mice with PMX53 (2mg/kg/day) in a prophylactic regimen for 
24 weeks inhibited diabetes-induced albuminuria (Fig. 4A), without affecting blood glucose (Table 
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2). Urinary 8-isoprostanes were reduced by PMX53 treatment in diabetic mice (Fig. 4B). Renal 
structural injury, as reflected by both the glomerulosclerotic index (Fig. 4D, E) and mesangial 
matrix expansion (Fig. 4F) was significantly decreased by PMX53. Similarly, renal fibrosis was 
decreased with PMX53 treatment in diabetic mice (collagen IV immunostaining, Fig. 4D, G and 
picrosirius red staining, Fig. 4D, H). 
Treatment with PMX53 was associated with a trend towards a reduction in infiltrating 
F4/80 positive macrophages into the tubulointerstitium in diabetic kidneys, although this was not 
statistically significant (Fig. 4D, I). Signaling through C5aR1 induces Th1 responses and inhibits 
induction of Treg (31-33). PMX53 has been shown to induce Treg activation (34). Indeed, PMX53 
treatment in the diabetic setting led to an increase in FoxP3+ Tregs within the kidney (Fig. 4D, J). 
Furthermore, the diabetes-induced increase in the pro-inflammatory cytokine IL-18 was 
significantly attenuated in the plasma of diabetic mice treated with PMX53 (Fig. 4C).
Inhibition of C5aR1 restores the mitochondrial fatty acid profile and cardiolipin remodelling in 
DKD
We next performed transcriptomic analysis on renal cortex using RNA-Seq. The diabetes gene 
signature was significantly modulated by PMX53 with almost half (49%) of the genes altered by 
diabetes restored by PMX53 (Fig. 5A). Interestingly, REACTOME gene set analysis identified 
that five out of the top 10 pathways that were downregulated by PMX53 in diabetes were involved 
in cellular metabolism, including glycolysis, mitochondrial fatty acid beta oxidation and fatty acyl 
CoA biosynthesis (Fig. 5B). Of interest, the top upregulated gene by PMX53 treatment in diabetes 
was the Acyl-CoA dehydrogenase family, member 10 (Acad10, log2 fold change, FDR 1.18E-
135), which was also the top downregulated gene in diabetes (log2 fold change, FDR 3.19E-132). 
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Acad10 is a member of the acyl-CoA dehydrogenase family of enzymes (ACADs), which 
participate in fatty acid oxidation (FAO) within mitochondria (35). Intriguingly, the majority of 
genes associated with mitochondrial fatty acid beta oxidation that were altered in diabetes were 
restored by PMX53 treatment (Fig. 5D and E, Table S3). Furthermore, only two out of 11 genes 
examined in the fatty acid metabolism pathway were significantly altered by PMX53 in the 
diabetic kidneys (Table S3). Validation by RT-qPCR also confirmed the Acad10 findings (Fig. 
5F). Furthermore, Acad10 expression, which was downregulated in the renal cortex in WT diabetic 
mice was restored in C5aR1-/- diabetic mice (Fig. 5G). 
The two key transcription factors responsible for the induction of lipogenic genes are sterol 
regulatory element binding protein (SREBP) and carbohydrate-responsive element-binding 
protein (ChREBP)(36; 37). To determine whether regulation of fatty acid synthesis was altered, 
RT-qPCR was used to determine gene expression of ChREBP and SREBP. Total ChREBP was 
decreased in diabetes and not altered with PMX53 (Fig. S4A) or C5aR1-/- (Fig. S4B). Similarly, 
ChREBP- was downregulated in diabetes and not altered with PMX53 (Fig. S4C) C5aR1-/- (Fig. 
S4D). In contrast, ChREBP- mRNA expression was highly upregulated in the kidney in the 
diabetic setting (~15-fold increase, Fig. S4E) and decreased in diabetic mice treated with PMX53. 
Interestingly, C5aR1-/- mice did not show a reduction in diabetes-induced ChREBP- gene 
expression (Fig. S4F). There was no change in SREBP-1a (Fig. S4G&H) or SREBP-2 (Fig. 
S4K&L). SREBP-1c, although unchanged in the diabetic kidney from the PMX53 study cohort 
(Fig. S4I), was decreased in the WT diabetic kidney in the C5aR1-/- study cohort and mRNA 
expression was restored in the diabetic C5aR1-/- mice (Fig. S4J). Since it is thought that ChREBP- 
expression best reflects total ChREBP lipogenic activity (38), these results suggest that fatty acid 
synthesis is increased in the diabetic kidney and normalized by PMX53.
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To gain insight into the fatty acid profile of the kidney, lipidomics was undertaken. 
Acylcarnitines are involved in fatty acid transport into the mitochondria for oxidation and are 
elevated when fatty acid oxidation is supressed. Alteration in the plasma acylcarnitine profile has 
been observed in abnormal fatty acid oxidation DKD (39). However, limited studies have reported 
acylcarnitine levels in the kidney of T1D. Lipidomics of renal cortex showed that levels of total 
(Fig. S2A), short (Fig S2D) and long chain acylcarnitines (Fig. 6A, Fig S2D) were downregulated 
in the diabetic kidney. Total acylcarnitines were also standardized to protein (Fig.  S2E) and 
showed the same trend as total acylcarnitines standardized to phosphatidylcholine (PC) (Fig. S2A). 
Inhibition of C5aR1 by PMX53 led to a restoration of total (Fig. S2A), short (Fig S2D) and long 
(Fig. 6A, Fig S2D) chain acylcarnitine species. Additional lipid species showed significant 
changes in the kidney of mice with diabetes (Fig. S2G and Table S4), including a decrease in 
ubiquinone (Table S4), a member of the mitochondrial electron transport chain.
Cardiolipin, which is a signature phospholipid of the inner mitochondrial membrane, is 
essential for optimal oxidative phosphorylation, mitochondrial architecture and mitophagy. 
Though the total cardiolipin content of the kidney was unchanged (Fig. S2B), we discovered 
striking changes to the composition of particular cardiolipin species in the diabetic kidney 
indicating cardiolipin remodelling (Fig. 6B and C).  Lipidomics identified a decrease in nine out 
of 38 cardiolipin species in the diabetic kidney, notably those containing omega-3 polyunsaturated 
fatty acyl chains (22:6) in addition to the typical linoleyl acyl chains (18:2) (Fig. 6B).  Conversely 
there was an increase in six out of the 38 cardiolipin species analysed (Fig. 6C), predominantly 
containing monounsaturated fatty acids (18:1) in addition to the linoleyl chains. This indicates loss 
of omega-3 polyunsaturated fatty acids from cardiolipin within the inner mitochondrial membrane 
and replacement with monounsaturated fatty acids at this site. PMX53 treatment restored the 
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composition of cardiolipin in diabetes (Fig. 6B, C), recapitulating a non-diabetic profile, 
suggesting that C5a may be a regulator of mitochondrial homeostasis and play a key role in 
metabolism. 
Diabetes induces changes to mitochondrial agility which are normalised by C5aR1 inhibition 
To explore the concept that the C5a/C5aR1 axis can promote changes in mitochondrial agility, 
targeted metabolomics was performed on renal cortex focusing on citric acid cycle metabolites. 
There was an increase in the citric acid cycle intermediates, cis-aconitate and isocitrate (Fig. 6D), 
indicating increased flux through the citric acid cycle. Lending further weight to the role of 
C5a/C5aR1 on metabolism, PMX53 treatment was able to restore levels of citric acid cycle 
intermediates to control levels. 
Proof of concept studies were then performed to determine a direct effect of C5a on 
mitochondrial bioenergetics. Mitochondrial respiratory function was assessed in human primary 
proximal tubule cells (PTECs) using the Seahorse flux analyzer. Although PTECs exposed to 
human C5a for 24 hours did not display significantly altered basal mitochondrial oxygen 
consumption, C5a treatment increased mitochondrial respiration following FCCP-stimulated 
mitochondrial uncoupling (UCP) and ATP-linked respiration (Fig. 6E), both of which were 
normalized with PMX53. Finally, reactive oxygen species generation, as measured by DCFDA 
fluorescence, was heightened with C5a treatment and attenuated with PMX53 (Fig. 6F). These 
studies indicate that the C5a/C5aR1 axis can indeed promote changes in mitochondrial metabolic 
agility.
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Discussion 
The current report, including both clinical and pre-clinical studies, emphasizes a potential role for 
C5a in the progression of DKD and as an attractive therapeutic target for renoprotection in the 
setting of diabetes. Collectively, these studies show that C5a-C5aR1 signalling is involved in renal 
disease initiation and progression via changes in mitochondrial agility, specifically through 
changes in cardiolipin remodelling, mitochondrial metabolite flux and mitochondrial respiratory 
function.
Although the liver is the primary site of complement synthesis (40), local production of 
complement in the kidney, particularly within renal tubules could contribute to tissue injury in a 
variety of renal diseases (41). C5aR1 has been shown to be expressed on proximal tubular cells 
(42), podocytes (43), fibroblasts (44), mesangial cells, vascular endothelial and smooth muscle 
cells (11). Genome-wide transcriptome analysis showed upregulation of the complement pathway 
in microdissected human renal glomerular and tubule samples from patients with DKD (45).  
Indeed, renal cortical expression of C5aR1 was increased early after the onset of diabetes in STZ-
diabetic rats, before the development of albuminuria, and urinary excretion of C5a was evident 
later in diabetes, which persisted over diabetes duration. Upregulation of C5aR1 was also found 
in the liver of the db/db mouse model and in the STZ mouse model, reflective also of systemic 
complement activation.  Thus, it appears that diabetes is a state of C5a activation at both a systemic 
and local tissue level. A finding pertinent for translation is that plasma C5a was not reduced in 
patients with type 1 diabetes or type 2 diabetes treated with conventional RAS inhibitors compared 
to untreated diabetic individuals, indicating that the C5a-C5aR1 signalling pathway is a pathogenic 
pathway not effectively targeted or suppressed by conventional renoprotective therapies.
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In human diabetes, plasma C5a was positively associated with urinary albumin (r=0.25), though 
this was a weak correlation, as it did not reach statistical significance (p=0.09). Plasma C5a was 
negatively correlated with eGFR (r=-0.32), however, this association did not reach significance 
(p=0.06). In the STZ mouse model, there was a highly significant correlation between urinary C5a 
and urinary albumin (r=0.80, p<0.0001).  Whilst the upstream events that lead to complement 
activation in diabetes are unknown, complement activation in this setting is likely to be glucose-
mediated. Whilst HbA1c was not correlated with plasma C5a in individuals with diabetes, the 
increase in plasma C5a may be related to the ambient glucose concentration or to other pro-
inflammatory stimuli that exist in the diabetic milieu.    
Increasing evidence indicates that defective FAO contributes to renal fibrosis in chronic kidney 
diseases such as DKD (46; 47). In the current study, transcriptomic analyses showed that genes 
associated with FAO that were altered in the diabetic kidney were restored by PMX53, specifically 
Acad10. Acad10 has only been recently identified as one of the long chain acyl-CoA 
dehydrogenases (LCAD) (35) and its expression in the kidney is largely restricted to mitochondria 
(48). Intriguingly, Acad10 was ranked among the top 1% for association with early onset of T2D 
in a genome wide association study in Pima Indians, a population with an extremely high 
prevalence of renal disease in the context of diabetes (49). However, its specific association with 
DKD has not been reported. In the current study, inhibition of C5aR1 by PMX53, or genetic 
deletion of C5aR1 restored the expression of Acad10 in the diabetic kidney, indicating that C5a-
C5aR1 signalling is involved in fatty acid homeostasis by suppressing the transcription of FAO 
enzymes such as Acad10. 
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L-Carnitine (levocarnitine; 3-hydroxy-4-N-trimethylaminobutyrate) plays a pivotal role in 
transporting fatty acids into the mitochondria for subsequent β-oxidation. Disturbances to the 
relative composition of the endogenous carnitine pool which is comprised of L-carnitine with 
short-, medium- and long-chain acylcarnitines is associated with impaired FAO and mitochondrial 
dysfunction (50). Literature describing the levels of acylcarnitines in DKD has primarily focused 
on plasma and/or urine, and results are conflicting (39). Although a recent study has shown that 
circulating long chain acylcarnitines are associated with incident renal functional decline in adults 
(51), it is well appreciated that plasma lipid profiles may not correlate with kidney tissue levels 
(52). Several studies have shown changes in kidney cortical acylcarnitine levels in T2D mouse 
models (53; 54). However, our study is the first, to our knowledge, to determine the acylcarnitine 
profile in the kidney in T1D. In our mouse model of STZ-diabetes, lipidomics showed 
acylcarnitines to be decreased in the renal cortex. Interestingly, these findings are in contrast to 
findings with respect to acylcarnitine levels from T2D db/db mice where levels of acylcarnitines 
were found to be increased in the kidney cortex at 24 weeks of age, indicating increased FAO flux 
(53). This is not totally surprising, since that model is driven by insulin resistance. Several other 
studies have also shown that higher acylcarnitines but lower TCA intermediates in the skeletal 
muscle in T2D may suggest that FAO flux does not match TCA flux, leading to incomplete FAO 
(55). Nonetheless, very little is known of the relationship between acylcarnitine content, FAO and 
TCA flux in the T1D kidney. We have shown here that TCA cycle intermediates such as cis-
aconitate and isocitrate are increased in the diabetic kidney, concomitant with reduced long chain 
acylcarnitine levels, which may suggest a dysregulation of FAO leading to a compensatory 
increase in these TCA metabolites. However, metabolic flux assays would be required to confirm 
specific changes in FAO. Most importantly, the role of C5a-C5aR1 in disturbing the mitochondrial 
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fatty acid signature in DKD is further substantiated by a restoration of the acylcarnitine profile and 
TCA intermediates in the diabetic renal cortex by PMX53. Indeed, Kang et al. (46) have shown 
that decreased tubule epithelial FAO induces metabolic reprogramming of tubular epithelial cells 
into a profibrotic phenotype. Thus, restoration of the mitochondrial fatty acid signature in the 
current study by inhibition of C5aR1 may be driving the attenuation of renal injury in STZ-induced 
diabetic mice. 
Cardiolipin, the “signature” phospholipid of the inner mitochondrial membrane, is crucial for 
optimal mitochondrial bioenergetics and dynamics (56). The appropriate fatty acid composition of 
cardiolipin is crucial for maintaining normal mitochondrial structure and function, including the 
curvature formation of the inner mitochondrial membrane (57) and stabilization of respiratory 
chain complexes (58). In the current study, the kidney from mice with diabetes exhibited a 
markedly distinct profile of cardiolipin species, with a decrease in species containing omega-3 
(22:6) fatty acids and an incorporation of species containing monounsaturated (oleic acid) fatty 
acids. Cardiolipin is highly sensitive to oxidative damage induced by reactive oxygen species, due 
to its high content of polyunsaturated fatty acids (59). Indeed, we found evidence of increased 
oxidative stress with increased lipid peroxidation (8-isoprostanes) in the diabetic kidney which 
may have precipitated cardiolipin remodelling. In the current study, inhibition of C5aR1 reversed 
the aberrant cardiolipin profile in the diabetic renal cortex, indicating that targeting the C5a-C5aR1 
axis could prevent detrimental cardiolipin remodelling and restore mitochondrial homeostasis in 
DKD. A recent study implicated a role for C5a-C5aR1 signalling in the regulation of lipid 
metabolism in diabetes, by using an aptamer to C5aR1 in a model of T2D (db/db mouse), which 
showed a reduction in serum triglycerides and a decrease in the expression of genes involved in 
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the regulation of fatty acid synthesis such as DGAT1 and SREBP-1 (60). The current study is the 
first to demonstrate that the C5a-C5aR1 axis may be is involved in mitochondrial cardiolipin 
remodeling, potentially resulting in a mitochondrial defect. 
Results from our studies have important clinical implications. The upstream positioning of 
complement in inflammatory propagation renders it an attractive system for targeted modulation 
(61). A suite of complement inhibitors have been developed which target complement at various 
stages of the activation pathway including at the level of C3 (e.g., Compstatin), C5 (e.g., 
Eculizumab) and C5aR1 (e.g., PMX53 and Avacopan) (61). However, selective targeting of 
C5a/C5aR1 is considered to be more amenable for chronic disease management since the immune 
defence functions of the proximal complement system, such as opsonization and formation of 
membrane attack complex, are preserved, while the properties of C5a that promote inflammation 
and metabolic reprogramming are impeded. PMX53, an orally active peptide antagonist of C5a 
(6), is one of the most widely studied and utilized inhibitors of C5aR1 in models of inflammatory 
diseases, albeit not previously in diabetes. Although PMX53 was determined to have rapid 
clearance/distribution and low oral bioavailability following administration to mice, it is a non-
competitive and effectively irreversible antagonist with extended pharmacodynamics following 
oral treatment (62). In the clinical context, early phase Ib/IIa trials for the treatment of rheumatoid 
arthritis have found PMX53 to be safe and well tolerated when administered orally (63). With the 
potential to advance into clinical development, this is the first study to use an orally bioavailable 
agent, PMX53, in the DKD setting.
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We note that there are limitations to this study: 1) RNA-Seq and lipidomics were performed on 
renal cortical tissue, so we cannot determine which cell types are most affected by diabetes and/or 
C5aR1 inhibition; 2) the role of an alternate anaphylatoxin of the complement system, C3a, which 
was also increased in the plasma of patients with diabetes, was not examined. However, dual 
function of C3a and its receptor C3aR, in the control of inflammation (64), as well as a lack of 
specific antagonists in clinical development (65) are major impediments to the translational 
potential of C3a; and finally 3) stable isotope flux analysis to assess fatty acid oxidation could not 
be performed.
In summary, this series of clinical, preclinical and in vivo mechanistic studies indicate that the 
C5a-C5aR1 signalling axis: (i) plays a crucial role in the pathogenesis of DKD via mitochondrial 
reprogramming, (ii) is not yet touched by conventional clinical therapies of DKD, (iii) may be 
directly targeted to in order to potentiate meaningful renoprotection in diabetes. Targeting the C5a-
C5aR1 pathway with orally bioavailable antagonists, such as PMX53, could potentially fulfil the 
unmet clinical need of treating and preventing the development of DKD, the major cause of end 
stage renal disease worldwide.
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Tables
Table 1: Basic characteristics of wildtype nondiabetic control, wildtype diabetic, C5aR1 
knockout (-/-) nondiabetic control and C5aR1-/- diabetic mice after 24 weeks of diabetes.
WT Con WT Diab C5aR1-/- Con C5aR1-/- Diab
BW, g 33.5±0.7 23.1±1.3**** 38.0±1.3* 23.3±0.8††††
Plasma 
glucose, mg/dL
284±19 629±56** 329±27 578±73**
HbA1c, % 
(mmol/mol)
4.3±0.04
(23±1)
13.3±0.3****
(120±3)
4.4±0.2
(21±1)
13.2±0.6††††
(120±7)
CrCl, 
ml/min/m2
18.9±2.5 30.6±7.8 27.0±8.6 26.3±3.4
Cystatin C, 
ng/ml
450.3±23.4 284.9±31.3*** 374.8±24.1 306.0±25.5**
L.Kid:BW, 
mg/g
4.8±0.2 11.6±0.8**** 5.1±0.3 10.8±.6††††
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs WT Con; ††P<0.01, †††P<0.001, ††††P<0.0001 
vs C5aR1-/- Con. Data are presented as mean±SEM.
BW = body weight; HbA1c = haemoglobin A1c; CrCl = creatinine clearance; L.Kid = left 
kidney; WT = wildtype; Con = control; Diab = diabetic.
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Table 2: Basic characteristics of nondiabetic control and STZ diabetic mice treated with 
vehicle or C5aR1 antagonist, PMX53 for 24 weeks.
Con Con+PMX53 Diab Diab+PMX53
BW, g 34±1 35±1 23±1**** 29±1*###
Plasma 
glucose, mg/dL
258±27 201±20 639±38**** 559±80***
HbA1c, % 
(mmol/mol)
5.0±0.2
(31±4)
5.4±0.1
(36±4)
12.2±1.4**
(123±3)
9.4 ±1.1
(79±12)
CrCl, 
ml/min/m2
17.7±4.5 15.7±1.8 28.4±5.2 28.7±3.4
Cystatin C, 
ng/ml
464.8±25.8 467.8±49.5 287.5±25.6** 373.4±32.2
L.Kid:BW, 
mg/g
5.368±0.218 5.355±0.190 10.67±0.541**** 7.923±0.245**###
****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 vs Con; ###P<0.001, #P<0.05 vs Diab.
BW = body weight; HbA1c = haemoglobin A1c; CrCl = creatinine clearance; L.Kid = left kidney; 
WT = wildtype; Con = control; Diab = diabetic.
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Figure legends
Fig. 1. Complement activation in patients with type 1 diabetes and type 2 diabetes is not 
targeted by classical clinical therapy. Plasma C5a (A), C3a (B) and C5b-9 (C) were measured 
in non-diabetic control individuals (Con, n=38), in patients with type 1 diabetes (T1D, n=18) or 
type 2 diabetes (T2D, n=20), and in patients with diabetes treated with renin-angiotensin system 
(RAS) inhibitors (T1D+RAS, n=19; T2+RAS, n=20). The line within the scatterplot represents 
the mean. Comparison between the groups was performed using one-way ANOVA followed by 
Tukey’s test. ***P<0.001 vs Con.
Fig. 2. The C5a/C5aR1 axis is upregulated in diverse mouse models of diabetes. (A) Renal 
cortical and (B) liver C3, C5 and C5aR1 expression in the Ins2-Akita mouse model (n=8-20 
mice per group, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs WT). (C) Urinary excretion 
of C5a in Ins2-Akita mice (n=8-13 mice per group, **P<0.01 vs WT). (D) Renal cortical and (E) 
liver C3, C5 and C5aR1 expression in the db/db mouse model (n=3-9 mice per group, *P<0.05, 
**P<0.01, ***P<0.001 vs db/h). (F) Urinary excretion of C5a in db/db mice (n=9-18 mice per 
group, ***P<0.001 vs db/h). STZ-diabetic rats were followed for 4, 8, 16 and 32 weeks and 
C5aR1 mRNA expression was determined (G) and urinary C5a excretion (H), n=6-10 rats per 
group. *P<0.05, **P<0.01 vs Con at the same timepoint. The line within the scatterplot 
represents the mean.
Fig. 3. Genetic deletion of C5aR1 protects against diabetes-induced inflammation and renal 
injury. Urinary albumin (A) and 8-isoprostane (B) were determined in wildtype control and 
diabetic mice and in C5aR1-/- control and diabetic mice. (C) F4/80+ cells in the renal cortex (C, E 
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top row). (D) FoxP3+ cells the renal cortex (D, E bottom row). Original magnification ×200. Scale 
bar = 50μm. n = 4-12 mice/group. *P<0.05, **P<0.01, ****P<0.0001 vs WT Con; #P<0.05, 
##P<0.01, ###P<0.001 vs WT Diab; ^^^P<0.001 vs C5aR1-/- Con. The line within the scatterplot 
represents the mean.
Fig. 4. C5aR1 inhibition by PMX53 is efficacious in DKD. Wildtype control and STZ-diabetic 
mice were treated with 2mg/kg/day PMX53 for 24 weeks and urinary albumin (A) 8-isoprostane 
(B) and plasma IL-18 (C) were determined. Renal histology was examined by staining paraffin-
embedded sections with Periodic acid-Schiff (PAS) and glomerulosclerotic index (D, E) and 
mesangial matrix expansion (D, F) was quantitated. Glomerular Collagen IV deposition was 
determined (D, G). Kidney fibrotic area was determined by picrorsirius red staining (D, H). 
Inflammatory F4/80+ cells (D, I) and anti-inflammatory FoxP3+ cells (D, J) in the kidney were 
examined by immunohistochemistry. Original magnification ×400 and scale bar = 25μm for PAS 
and Col IV. Original magnification ×200 and scale bar = 50μm for picrosirius red, F4/80 and 
FoxP3. n = 6-12 mice/group. *P<0.05, ***P<0.001, ****P<0.0001 vs Con; #P<0.05, ##P<0.01, 
####P<0.0001 vs Diab. The line within the scatterplot represents the mean.
Fig. 5. RNA-Seq analysis reveals a role for C5aR1 in pathways involved in mitochondrial 
fatty acid beta-oxidation. (A) Rank-rank density plot of differential gene expression due to 
diabetes and PMX53 treatment. (B) GSEA analysis of diabetes vs diabetes+PMX53 showing the 
top REACTOME pathways, with mitochondrial fatty acid beta-oxidation pathway highlighted red. 
(C) MA plot of top differential genes in diabetes vs diabetes+PMX53 groups with the top three 
downregulated and top three upregulated genes highlighted. (D) Rank-rank density plot of 
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differential genes in the mitochondrial fatty acid beta-oxidation pathway. (E) Gene set enrichment 
analysis highlighted genes that were altered by PMX53 in the mitochondrial fatty acid beta-
oxidation pathway in diabetic mice. (F) Acad10 expression in PMX53 treated mice and (G) 
C5aR1-/- mice. mice/group. n = 6-12, **P<0.01 vs Con or WT Con, ##P<0.01 vs Diab or WT Diab. 
The line within the scatterplot represents the mean.
Fig. 6. Diabetes induces changes to mitochondrial agility including kidney cardiolipin 
remodelling and enhanced TCA cycle intermediate generation, which are normalised by 
C5aR1 inhibition. Lipidomics of renal cortex was performed to determine (A) Acylcarnitine 
species and (B) Cardiolipin species that were downregulated in diabetes and restored by PMX53 
treatment, or (C) Cardiolipin species that were upregulated in diabetes and attenuated by PMX53 
treatment. Data are mean±SEM, n=6-12 mice/group. (D) TCA cycle intermediates in renal cortex 
were determined by metabolomics, n=6-12 mice/group. *P<0.05, ***P<0.001 vs Con, #P<0.05, 
##P<0.01, ###P<0.001 vs Diab. (E) Human primary proximal tubule epithelial cells (PTECs) were 
exposed to C5a or C5a plus PMX53 for 24 hours and mitochondrial oxygen consumption rate 
(OCR), including basal, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP)-
uncoupled (UCR), and ATP-linked respiration was determined by Seahorse Flux Analyzer. Values 
are mean±SEM, n≥9 replicates per group. *P<0.05 vs Con, #P<0.05 vs C5a-treated cells. (F) 
PTECs were exposed to C5a or C5a plus PMX53 for 24 hours and reactive oxygen species 
production was determined using the DCFDA probe with flow cytometry detection. Values are 
mean±SEM, n=3 replicates per group. *P<0.05 vs Con, #P<0.05 vs C5a-treated cells.
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 Figure 1. Complement activation in patients with type 1 diabetes and type 2 diabetes is not targeted by 
classical clinical therapy. Plasma C5a (A), C3a (B) and C5b-9 (C) were measured in non-diabetic control 
individuals (Con, n=38), in patients with type 1 diabetes (T1D, n=18) or type 2 diabetes (T2D, n=20), and 
in patients with diabetes treated with renin-angiotensin system (RAS) inhibitors (T1D+RAS, n=19; T2+RAS, 
n=20). The line within the scatterplot represents the mean. Comparison between the groups was performed 
using one-way ANOVA followed by Tukey’s test. ***P<0.001 vs Con. 
92x191mm (300 x 300 DPI) 
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 Figure 2. The C5a/C5aR1 axis is upregulated in diverse mouse models of diabetes. (A) Renal cortical and (B) 
liver C3, C5 and C5aR1 expression in the Ins2-Akita mouse model (n=8-20 mice per group, *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 vs WT). (C) Urinary excretion of C5a in Ins2-Akita mice (n=8-13 
mice per group, **P<0.01 vs WT). (D) Renal cortical and (E) liver C3, C5 and C5aR1 expression in the 
db/db mouse model (n=3-9 mice per group, *P<0.05, **P<0.01, ***P<0.001 vs db/h). (F) Urinary 
excretion of C5a in db/db mice (n=9-18 mice per group, ***P<0.001 vs db/h). STZ-diabetic rats were 
followed for 4, 8, 16 and 32 weeks and C5aR1 mRNA expression was determined (G) and urinary C5a 
excretion (H), n=6-10 rats per group. *P<0.05, **P<0.01 vs Con at the same timepoint. The line within the 
scatterplot represents the mean. 
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 Figure 3. Genetic deletion of C5aR1 protects against diabetes-induced inflammation and renal injury. Urinary 
albumin (A) and 8-isoprostane (B) were determined in wildtype control and diabetic mice and in C5aR1-/- 
control and diabetic mice. (C) F4/80+ cells in the renal cortex (C, E top row). (D) FoxP3+ cells the renal 
cortex (D, E bottom row). Original magnification ×200. Scale bar = 50μm. n = 4-12 mice/group. *P<0.05, 
**P<0.01, ****P<0.0001 vs WT Con; #P<0.05, ##P<0.01, ###P<0.001 vs WT Diab; ^^^P<0.001 vs 
C5aR1-/- Con. The line within the scatterplot represents the mean. 
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 Figure 4. C5aR1 inhibition by PMX53 is efficacious in DKD. Wildtype control and STZ-diabetic mice were 
treated with 2mg/kg/day PMX53 for 24 weeks and urinary albumin (A) 8-isoprostane (B) and plasma IL-18 
(C) were determined. Renal histology was examined by staining paraffin-embedded sections with Periodic 
acid-Schiff (PAS) and glomerulosclerotic index (D, E) and mesangial matrix expansion (D, F) was 
quantitated. Glomerular Collagen IV deposition was determined (D, G). Kidney fibrotic area was determined 
by picrorsirius red staining (D, H). Inflammatory F4/80+ cells (D, I) and anti-inflammatory FoxP3+ cells (D, 
J) in the kidney were examined by immunohistochemistry. Original magnification ×400 and scale bar = 
25μm for PAS and Col IV. Original magnification ×200 and scale bar = 50μm for picrosirius red, F4/80 and 
FoxP3. n = 6-12 mice/group. *P<0.05, ***P<0.001, ****P<0.0001 vs Con; #P<0.05, ##P<0.01, 
####P<0.0001 vs Diab. The line within the scatterplot represents the mean. 
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 Figure 5. RNA-Seq analysis reveals a role for C5aR1 in pathways involved in mitochondrial fatty acid beta-
oxidation. (A) Rank-rank density plot of differential gene expression due to diabetes and PMX53 treatment. 
(B) GSEA analysis of diabetes vs diabetes+PMX53 showing the top REACTOME pathways, with mitochondrial 
fatty acid beta-oxidation pathway highlighted red. (C) MA plot of top differential genes in diabetes vs 
diabetes+PMX53 groups with the top three downregulated and top three upregulated genes highlighted. (D) 
Rank-rank density plot of differential genes in the mitochondrial fatty acid beta-oxidation pathway. (E) Gene 
set enrichment analysis highlighted genes that were altered by PMX53 in the mitochondrial fatty acid beta-
oxidation pathway in diabetic mice. (F) Acad10 expression in PMX53 treated mice and (G) C5aR1-/- mice. 
mice/group. n = 6-12, **P<0.01 vs Con or WT Con, ##P<0.01 vs Diab or WT Diab. The line within the 
scatterplot represents the mean. 
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 Figure 6. Diabetes induces changes to mitochondrial agility including kidney cardiolipin remodelling and 
enhanced TCA cycle intermediate generation, which are normalised by C5aR1 inhibition. Lipidomics of renal 
cortex was performed to determine (A) Acylcarnitine species and (B) Cardiolipin species that were 
downregulated in diabetes and restored by PMX53 treatment, or (C) Cardiolipin species that were 
upregulated in diabetes and attenuated by PMX53 treatment. Data are mean±SEM, n=6-12 mice/group. (D) 
TCA cycle intermediates in renal cortex were determined by metabolomics, n=6-12 mice/group. *P<0.05, 
***P<0.001 vs Con, #P<0.05, ##P<0.01, ###P<0.001 vs Diab. (E) Human primary proximal tubule 
epithelial cells (PTECs) were exposed to C5a or C5a plus PMX53 for 24 hours and mitochondrial oxygen 
consumption rate (OCR), including basal, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP)-
uncoupled (UCR), and ATP-linked respiration was determined by Seahorse Flux Analyzer. Values are 
mean±SEM, n≥9 replicates per group. *P<0.05 vs Con, #P<0.05 vs C5a-treated cells. (F) PTECs were 
exposed to C5a or C5a plus PMX53 for 24 hours and reactive oxygen species production was determined 
using the DCFDA probe with flow cytometry detection. Values are mean±SEM, n=3 replicates per group. 
*P<0.05 vs Con, #P<0.05 vs C5a-treated cells. 
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Online Supplementary Materials 
Method for PMX53 Pharmacokinetics 
C57BL/6 J mice (males, 10–12 weeks old) were purchased from Animal Resources Centre, 
Western Australia. After overnight fasting, mice (n = 4 per time point) were anaesthetized 
with zolazapam (50 mg/kg) and xylazine (12 mg/kg) via i.p. injection. Anaesthetized mice 
were administered 1 mg/kg of PMX53 in 5% dextrose water for injection either through the 
tail vein for intravenous route (i.v.) or by oral gavage for per-oral route (p.o.). Blood samples 
were collected from separate mice via cardiac puncture at 2.5 min, 5 min, 10 min, 15 min, 
30 min, 45 min, 60 min and 90 minutes in tubes containing EDTA followed by plasma 
separation by centrifugation at 1500 × g at 4 °C. Plasma samples were stored at -80 °C for 
further processing and analysis. On the day of analysis, 50 µl of plasma was mixed with 10 µl 
of 1 µg/ml of internal standard (PMX205) and processed for quantitative analysis of PMX53 
using a validated LC-MS/MS method 71. Pharmacokinetic data analysis was performed using 
Pharsight WINNONLIN software (version 6.4) to obtain various pharmacokinetic parameters 
along with PMX53 bioavailability determination.
Method for the Measurement of Polar Acylcarnitines
Analysis of polar acylcarnitines was done using HILIC chromatography in conjunction with 
an Agilent 6490 QQQ mass spectrometer. Solvent A contains 95% acetonitrile, 5% water, 
10mM ammonium formate and 0.1% formic acid while solvent B comprising of 50% 
acetonitrile, 50% water, 10mM ammonium formate and 0.1% formic acid. Separation was 
performed at a flow rate of 0.4ml/minute on an InfinityLab Poroshell 120 HILIC-Z column 
(2.1 x 100 mm, 2.7 m) with the following conditions; Solvent B starting at 0%, holding 
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2isocratic for 1 minute before ramping to 100% solvent B over 5 minutes. The method was 
held at 100% B for 1 minute before returning to 0% B over 0.1 minutes. The column was 
then equilibrated with 0% B for 5.9 minutes for a total run time of 13 minutes.
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Fig. S1. Pharmacokinetic determination of PMX53 plasma concentrations in mice.
C57Bl/6J mice were injected intravenously (i.v.) or by oral gavage (p.o.) with PMX53 
(1mg/kg), and blood collected from separate mice at various time points up to 90 minutes 
post-injection. Data points represent individual values (mean±SEM; n=4 mice), and lines 
represent predicted values using two-compartmental analysis.
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4Fig. S2. Profile of acylcarnitine, cardiolipin and other lipid species in renal cortex.
(A) Total acylcarnitine levels in the renal cortex. (B) Total cardiolipin levels in the renal 
cortex. (C) Abundant cardiolipin species in the renal cortex not altered by diabetes and/or 
PMX53 treatment. (D) Short and long chain acylcarnitines were detected by HILIC method. 
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5(E) Total acylcarnitine levels in the renal cortex normalized to total protein. (F) PC(38:6), (G) 
PC(40:6) and (H) Free fatty acid (22:6) were also measured. Cardiolipin species normalized 
to total protein: (I) total cardiolipins, (J) downregulated cardiolipin species, (K) upregulated 
cardiolipin species. Data are mean±SEM, n=6-12 mice/group. *P<0.05, **P<0.01 vs Con, 
#P<0.05, ##P<0.01 vs Diab.
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6Fig. S3. Metabolomic analyses of kidney cortex.
PCA plot and showing TCA cycle metabolites in renal cortex from control and 
streptozotocin-induced diabetic C57BL/6 mice treated with or without PMX53.
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7Fig. S4. Renal cortical gene expression of transcription factors involved in fatty acid 
synthesis. (A) Total chREBP in control and diabetic mice with or without PMX53 treatment. 
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8(B) Total chREBP in control and diabetic mice with C5aR1 genetic deletion. (C) chREBP-
alpha in control and diabetic mice with or without PMX53 treatment. (D) chREBP-alpha in 
control and diabetic mice with C5aR1 genetic deletion. (E) chREBP-beta in control and 
diabetic mice with or without PMX53 treatment. (F) chREBP-beta in control and diabetic 
mice with C5aR1 genetic deletion. (G) SREBP-1a in control and diabetic mice with or 
without PMX53 treatment. (H) SREBP-1a in control and diabetic mice with C5aR1 genetic 
deletion. (I) SREBP-1c in control and diabetic mice with or without PMX53 treatment. (J) 
SREBP-1c in control and diabetic mice with C5aR1 genetic deletion. (K) SREBP-2 in control 
and diabetic mice with or without PMX53 treatment. (L) SREBP-2 in control and diabetic 
mice with C5aR1 genetic deletion. Data are mean±SEM, n=6-12 mice/group. *P<0.05, 
**P<0.01, ***P<0.001.
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9Fig. S5. Correlation analyses of C5a and albuminuria or eGFR in the setting of diabetes. 
Pearson’s correlation analysis was used to determine the relationship between: (A) plasma 
C5a and urine albumin in human diabetes, (B) plasma C5a and eGFR in human diabetes, (C) 
urinary C5a and urinary albumin in the STZ mouse model of diabetes. 
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Supplementary Tables
Table S1. Clinical characteristics of participants from which plasma was obtained for 
complement measurement.  
Control 
(n=38)
Type 1 
diabetes
(n=18)
Type 2 
diabetes
(n=20)
Type 1 
diabetes + 
RAS
(n=19)
Type 2 
diabetes  
+ RAS
(n=20)
Gender (M/F) 15/23 10/8 11/9 14/5 13/7
Age (years) 4611 4015 639 6313 6810
eGFR 
(ml/min/1.73m2) NA 838 7418 7115 7020
Urinary 
albumin 
(g/min)
NA 86 2045 87260 4588
Data are meanSD.
Table S2. PMX53 pharmacokinetic parameters.
Parameters* Units p.o. route i.v. route
Tmax min 20.32 ---
Cmax µg/mL 0.24 17.42
Alpha_HL min 14.04 3.49
Beta_HL min 22.89 14.73
MRTlast min 28.00 13.21
MRTINF_obs min 29.83 18.03
MRTINF_pred min 29.90 17.92
AUC (min*µg/ml) 11.78 204.63
Bioavailability % 5.7 100
*where Tmax represents time corresponding to max plasma conc. of PMX53; C max, max 
concentration of PMX53; Alpha HL represents distribution half-life; Beta HL represents 
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elimination half-life; MRT, mean residence time; and AUC is area under the concentration-
time curve from time zero to time t i.e. 90 min.
Table S3. Kidney cortex mRNA expression of genes involved in mitochondrial fatty acid 
β-oxidation and fatty acid metabolism in streptozotocin-induced diabetic mice treated 
with or without PMX53.
Pathway Gene Name
Gene 
Symbol
Log2 
Fold 
Change FDR
Enoyl-Coenzyme A delta isomerase 1 Eci1 -0.5348 3.33E-08
hydroxyacyl-CoA dehydrogenase 
trifunctional multienzyme complex 
subunit alpha
Hadha -0.33607 8.32E-07
Acyl-CoA dehydrogenase, long chain Acadl -0.18593 0.000101
Methylmalonyl CoA epimerase Mcee -0.14891 0.000576
Propionyl-CoA carboxylase subunit 
alpha
Pcca 0.167554 0.010026
Acyl-Coenzyme A dehydrogenase, very 
long chain
Acadvl -0.15296 0.010206
2,4-dienoyl CoA reductase 1, 
mitochondrial
Decr1 -0.2117 0.018426
Propionyl Coenzyme A carboxylase, beta 
polypeptide
Pccb 0.142277 0.018636
Acyl-Coenzyme A dehydrogenase, 
medium chain
Acadm -0.16853 0.035528
Acyl-Coenzyme A dehydrogenase, short 
chain
Acads 0.223574 0.051019
Methylmalonyl-Coenzyme A mutase Mut 0.086252 0.165725
Enoyl Coenzyme A hydratase, short 
chain, 1, mitochondrial
Echs1 -0.07282 0.169622
Mitochondrial 
fatty acid β-
oxidation
Hydroxyacyl-Coenzyme A 
dehydrogenase
Hadh 0.024264 0.801194
Enoyl-Coenzyme A delta isomerase 1 Eci1 -0.5348 3.33E-08
Acetyl-Coenzyme A acetyltransferase 1 Acat1 0.257547 0.006373
Acyl-CoA synthase Acss2 0.182849 0.132779
Acetyl-Coenzyme A carboxylase alpha Acaca 0.124141 0.206389
Methylmalonyl-Coenzyme A mutase Mut 0.086252 0.165725
Catalase Cat 0.079878 0.274439
Carnitine palmitoyltransferase 1c Cpt1c -0.10544 0.467711
Fatty acid synthase Fasn -0.0415 0.684343
Carnitine palmitoyltransferase 1a Cpt1a -0.03072 0.774633
Fatty acid 
metabolism
Hydroxyacyl-Coenzyme A 
dehydrogenase
Hadh 0.024264 0.801194
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Enoyl-Coenzyme A, hydratase/3-
hydroxyacyl Coenzyme A 
dehydrogenase
Ehhadh -0.02053 0.916932
Log2 Fold Change is Diab vs Diab+PMX53. Significance was defined as FDR < 0.05.
Table S4. Raw data of lipid species determined in the kidney of streptozotocin-induced 
diabetic mice treated with or without PMX53.
Lipid species Con(n=7)
Con+PMX53
(n=9)
Diab
(n=7)
Diab+PMX53
(n=8)
ANOVA
 p value 
(BH)
AC(14:0) 3.5±0.3 3.6±0.4 1.2±0.1 3.2±0.4 7.64E-05
AC(16:0) 22.5±1.4 24.8±2.4 6.2±0.6 19.1±1.9 4.14E-06
AC(16:1) 2.8±0.3 3.0±0.3 1.1±0.1 2.1±0.2 2.19E-04
AC(17:0) 6.9±0.6 7.8±1.7 4.7±0.7 7.3±1.0 3.60E-01
AC(18:0) 24.5±2.0 26.1±4.2 9.2±1.4 29.1±6.0 1.96E-02
AC(18:1) 16.6±1.2 19.0±0.9 10.9±1.5 18.1±1.5 1.34E-03
AC(18:2) 3.0±0.1 3.5±0.2 2.0±0.2 3.7±0.3 2.86E-04
PC(28:0) 77.3±7.8 79.3±7.3 73.3±3.1 58.8±8.8 2.47E-01
PC(14:0_16:0) 6897±228 6796±204 5135±333 5686±606 1.32E-02
PC(31:1) 129±8.0 147±9.6 252±27.7 129±9.1 3.03E-05
PC(31:0) 3470±141 3740±157 3799±208 4278±265 8.63E-02
PC(32:2) 721±33.0 792±34.3 1248±129 640±60.3 3.96E-05
PC(32:1) 10700±294 11244±503 11796±1079 8282±1246 5.88E-02
PC(16:0_16:0) 168486±2796 167850±1659 113272±7177 152330±4672 2.68E-08
PC(33:2) 745±37.7 811±36.3 1205±70.9 1027±108 8.56E-04
PC(33:1) 2315±62.3 2479±97.8 3044±111 2496±83.5 2.13E-04
PC(33:0) 2654±107 2877±138 3104±140 3332±259 9.21E-02
PC(34:5) 21.9±1.0 22.5±0.9 89.8±11.5 23.1±1.2 1.00E-08
PC(14:0_20:4) 180±11.4 192±10.9 353±38.6 178±12.8 1.39E-05
PC(16:1_18:2)\PC(16:0_1
8:3) 7957±186 8117±327 20599±1089 8197±316 1.64E-13
PC(16:0_18:2) 120391±3666 117904±3463 107515±3279 118445±4594 1.63E-01
PC(16:0_18:1) 120404±1489 124024±1546 157115±2766 123310±4093 1.00E-08
PC(16:0_18:0) 19012±450 18172±244 20179±463 19305±449 1.93E-02
PC(35:5) 27.2±1.5 28.1±1.0 69.1±6.9 31.9±1.8 2.68E-08
PC(15:0_20:4) 354±23.0 382±19.7 312±23.3 440±34.1 2.20E-02
PC(35:3) 384±15.9 409±12.6 536±24.5 431±20.9 1.07E-04
PC(35:2) 1484±49.9 1611±41.7 2351±78.3 2084±218 2.79E-04
PC(35:1) 418±19.6 444±15.8 447±22.3 425±15.9 6.51E-01
PC(36:6) 758±49.0 749±26.9 764±45.5 616±71.8 1.79E-01
PC(36:5) 7192±473 6943±513 9969±882 6527±590 5.57E-03
PC(18:2_18:2)\PC(16:0_2
0_4) 83721±2868 82334±2782 52537±469 84246±1671 3.90E-09
PC(36:2) 74881±1760 72943±2638 140753±7353 83607±4433 1.08E-09
PC(18:0_18:1) 8795±225 8978±203 9091±405 9084±187 8.57E-01
PC(36:0) 389±9.0 406±14.5 548±15.0 445±15.1 4.61E-07
PC(15:0_22:6) 1240±69.3 1338±76.6 1377±62.9 1488±102 2.71E-01
PC(15-
MHDA_20:4)\PC(17:0_2
0:4) 2163±71.2 2279±65.7 1524±71.4 2682±199 1.93E-05
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Lipid species Con(n=7)
Con+PMX53
(n=9)
Diab
(n=7)
Diab+PMX53
(n=8)
ANOVA
 p value 
(BH)
PC(38:7) 7299±269 6806±176 7542±334 5342±444 4.44E-04
PC(38:6) 109692±3864 110430±5197 88374±1999 107436±2748 2.91E-03
PC(38:5) 44948±762 46752±616 54652±1323 48533±1379 2.78E-05
PC(38:4) 63917±1300 65409±1590 53907±1898 76520±2374 4.90E-07
PC(18:0_20:3) 6589±261 6119±157 7751±403 5930±158 2.79E-04
PC(38:2) 21882±532 21199±416 25802±1037 20536±526 6.28E-05
PC(39:6) 4224±219 4500±226 2959±253 4905±393 1.09E-03
PC(39:5) 664±47.3 601±15.9 659±32.1 623±29.2 4.76E-01
PC(40:10) 50.9±2.7 46.6±3.2 91.1±8.9 41.7±3.3 2.38E-06
PC(40:8) 13154±489 12633±174 15369±798 14185±716 1.90E-02
PC(40:7) 20242±574 20151±205 33224±2434 19655±547 6.99E-08
PC(18:0_22:6) 52798±1149 52445±1361 30893±2212 47317±1522 8.37E-09
PC(18:0_22:5) 6240±154 6496±146 7492±315 6399±266 6.52E-03
PC(18:0_22:4)\PC(20:0_2
0:4) 1764±27.8 1847±41.3 1396±111 2102±88.7 2.11E-05
PC(44:12) 570±27.3 474±10.4 833±58.8 652±52.4 3.59E-05
TG(48:0) [NL-16:0] 6087±520 5912±410 1785±144 4202±659 1.41E-05
TG(48:0) [NL-18:0] 313±24.9 331±24.2 221±12.9 280±12.2 6.70E-03
TG(48:1) [NL-16:1] 1577±214 1583±143 796±53.5 1080±100 1.83E-03
TG(48:1) [NL-18:1] 1424±196 1377±113 696±75.0 938±119 2.61E-03
TG(48:2) [NL-14:0] 818±129 835±117 276±39.1 557±156 1.90E-02
TG(48:2) [NL-14:1] 180±30.3 204±26.6 240±65.6 133±9.9 2.85E-01
TG(48:2) [NL-16:1] 1589±252 1662±164 1132±85.3 1215±62.2 7.91E-02
TG(48:2) [NL-18:2] 894±123 860±73.5 264±34.5 572±140 1.39E-03
TG(48:3) [NL-14:0] 143±34.2 142±22.7 75.6±18.7 87.4±29.7 2.38E-01
TG(48:3) [NL-16:1] 569±90.1 609±60.4 468±50.1 462±26.8 2.70E-01
TG(48:3) [NL-18:3] 83.3±15.9 78.5±7.7 59.0±13.4 51.5±15.8 3.30E-01
TG(48:3) [SIM] 1031±164 1111±123 856±170 782±99.9 3.46E-01
TG(49:1) [NL-16:1] 281±21.2 321±43.4 250±14.4 282±19.7 4.55E-01
TG(50:0) [NL-18:0] 445±64.6 423±32.7 216±16.4 345±24.8 2.49E-03
TG(50:1) [NL-18:1] 5380±893 4416±664 1698±257 3412±582 7.96E-03
TG(50:2) [NL-18:2] 3527±432 3193±322 656±116 2162±395 5.93E-05
TG(50:3) [NL-18:3] 499±63.1 447±47.5 229±54.0 284±71.1 1.88E-02
TG(50:4) [NL-20:4] 119±29.6 109±18.9 19.2±4.0 56.4±5.7 3.07E-03
TG(51:0) [SIM] 2638±624 2229±224 1525±183 1966±176 2.22E-01
TG(54:0) [NL-18:0] 179±9.9 191±13.1 163±6.7 183±5.8 3.09E-01
TG(54:1) [NL-18:1] 91.5±12.4 92.6±9.2 60.4±5.3 76.2±9.3 1.12E-01
TG(54:1) [SIM] 449±39.1 473±40.1 335±21.9 408±32.1 7.91E-02
TG(54:2) [NL-18:0] 1174±190 1355±235 773±109 1591±640 5.30E-01
TG(54:3) [SIM] 2793±684 2866±619 1738±274 2520±632 5.73E-01
TG(54:4) [NL-18:2] 533±112 521±94.7 322±41.7 570±195 5.73E-01
TG(56:6) [NL-22:5](a) 145±26.7 134±18.1 63.9±14.4 86.6±12.8 2.33E-02
TG(56:6) [NL-22:5](b) 145±26.7 134±18.1 63.9±14.4 86.6±12.8 2.33E-02
TG(56:6) [SIM] 2483±317 2270±184 1548±318 1798±263 1.15E-01
TG(56:7) [NL-20:4] 873±127 1169±213 789±240 1142±460 7.60E-01
TG(56:7) [SIM] 5550±796 4573±498 3288±804 3162±446 6.66E-02
TG(56:8) [NL-20:4] 214±36.1 227±22.7 152±47.1 216±72.4 7.25E-01
TG(56:9) [NL-22:6] 152±40.6 114±18.9 180±70.7 72.2±12.9 3.04E-01
TG(58:10) [NL-22:6] 489±77.9 383±43.3 381±138 291±41.8 4.40E-01
TG(58:8) [NL-22:6] 353±68.8 270±20.6 361±121 237±40.7 5.33E-01
TG(58:9) [NL-22:6] 479±97.8 346±29.8 367±132 297±68.0 5.33E-01
Ubiquinone 235066±14941 204603±12997 158334±4738 199733±13708 6.77E-03
CL 34:1_32:2 51.3±4.5 46.7±3.7 53.5±7.2 36.5±8.4 2.92E-01
CL 34:1_34:4 4.5±1.0 4.8±1.1 23.8±1.8 4.6±0.7 1.23E-10
CL 34:1_34:3 77.2±4.1 68.6±4.9 115±10.1 62.4±12.4 2.01E-03
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Lipid species Con(n=7)
Con+PMX53
(n=9)
Diab
(n=7)
Diab+PMX53
(n=8)
ANOVA
 p value 
(BH)
CL 34:1_34:1 1941±114 1807±76.9 1314±87.1 1744±186 1.99E-02
CL 18:2_18:2_18:2_16:1 1885±120 1823±82.2 1253±111 1193±224 4.32E-03
CL 18:2_18:2_18:1_16:1 1147±71.0 1095±55.7 996±60.1 914±113 2.38E-01
CL 18:2_18:1_18:2_16:1 1113±83.4 1053±57.8 1011±93.0 713±172 9.68E-02
CL 18:1_18:1_18:2_16:1 57.4±6.4 57.0±4.4 168±18.3 43.2±8.5 5.24E-08
CL 18:2_18:1_18:1_16:1 1454±97.5 1336±68.1 1409±73.4 1129±163 2.35E-01
CL 18:2_18:2_18:2_18:3 336±21.8 296±11.7 1445±125 445±53.0 5.71E-11
CL 18:2_18:2_18:2_18:2 22750±994 21794±1103 21434±1454 26787±2138 8.95E-02
CL 18:2_18:2_18:2_18:1 13190±627 12734±451 12824±663 12887±290 9.32E-01
CL 18:2_18:2_18:1_18:1 678±46.1 712±37.1 2003±206 757±32.8 8.37E-09
CL 18:2_18:1_18:2_18:1 14559±854 13854±645 15539±971 13226±1005 3.47E-01
CL 18:2_18:1_18:1_18:1 648±52.8 679±44.0 2225±275 730±56.7 4.31E-08
CL 18:2_16:1_18:2_22:6 107±9.1 105±7.5 45.8±6.7 60.3±17.8 2.10E-03
CL 18:2_18:2_16:1_22:6 101±10.1 103±8.9 128±7.4 79.6±8.9 1.70E-02
CL 36:4_38:6 991±56.9 966±50.0 630±33.4 940±33.7 6.28E-05
CL 18:2_18:2_18:2_20:4 1479±64.4 1446±53.8 955±46.1 1430±47.6 2.38E-06
CL 18:2_18:2_18:2_20:3 3646±156 3435±138 2063±116 3291±80.4 8.72E-08
CL 18:2_18:1_18:2_20:3 1651±104 1533±81.8 1278±76.7 1441±90.5 7.91E-02
CL 18:2_18:2_18:1_20:3 1544±77.8 1389±65.9 988±58.5 2554±385 2.86E-04
CL 18:2_18:2_18:1_20:2 199±11.2 197±9.9 356±20.7 338±45.2 2.33E-04
CL 18:2_18:1_18:2_20:2 1221±71.3 1121±59.5 1020±67.0 1839±167 6.28E-05
CL 18:2_18:2_18:1_20:1 9.8±1.4 6.6±1.2 33.5±3.8 17.0±2.3 2.25E-07
CL 18:2_18:1_18:2_20:1 146±9.9 144±9.4 322±30.4 204±17.5 1.87E-06
CL 18:2_18:2_18:2_22:6 1734±96.2 1579±53.5 588±43.4 1228±85.7 2.23E-09
CL 18:2_18:2_18:1_22:6 521±35.7 457±16.1 338±16.3 402±23.8 3.03E-04
CL 18:2_18:1_18:2_22:6 2085±118 1977±67.7 770±66.9 1514±171 2.98E-07
CL 18:2_18:1_18:2_22:5 581±33.7 539±17.2 405±22.6 464±47.1 7.26E-03
CL 18:2_18:2_18:1_22:5 87.8±4.3 86.9±4.1 41.8±4.4 70.9±7.1 1.39E-05
CL 18:2_18:2_20:3_22:6 61.7±8.3 47.5±4.2 12.3±4.4 30.5±5.6 6.09E-05
CL 18:2_22:6_18:2_20:3 393±24.8 347±14.3 92.8±15.2 266±29.5 2.65E-08
CL 20:3_22:6_18:2_18:1 75.4±8.9 69.7±10.1 20.7±1.4 49.1±14.0 7.62E-03
CL 18:1_20:3_18:2_22:6 431±29.2 379±14.9 120±12.5 443±33.5 1.45E-08
CL 18:1_22:6_18:2_20:3 138±13.5 130±8.1 66.8±4.6 97.5±10.7 2.39E-04
CL 18:2_18:2_22:6_22:6 8.7±2.5 6.3±1.7 1.8±0.7 5.5±1.3 8.95E-02
CL 18:2_22:6_18:2_22:6 179±11.4 152±6.2 34.9±2.8 100±18.3 9.72E-08
AC(2:0) 174±19.6 149±16.1 63.5±7.4 170±18.0 5.32E-04
AC(4:0) 24.2±3.0 20.7±2.8 17.2±8.1 22.8±4.1 7.79E-01
AC(6:0) 1.3±0.3 1.0±0.1 0.5±0.2 1.2±0.3 9.34E-02
AC(8:0) 1.4±0.2 0.9±0.1 0.8±0.2 1.5±0.6 3.99E-01
AC(10:0) 0.3±0.0 0.2±0.0 0.1±0.0 0.3±0.1 2.50E-01
AC(12:0) 1.2±0.1 1.0±0.1 0.8±0.1 1.6±0.5 3.04E-01
AC(20:4) 1.1±0.1 1.2±0.1 0.9±0.1 1.8±0.2 3.69E-04
AC(22:6) 1.2±0.1 1.5±0.2 0.8±0.1 1.7±0.1 8.50E-04
Data are meanSEM. p-values corrected for multiple comparisons by the method of 
Benjamini and Hochberg. Significant corrected p-values (<0.05) shown in bold. 
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